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Abstract Glycogen storage disease type III (GSDIII) is a rare
disorder of glycogenolysis due to AGL gene mutations, caus-
ing glycogen debranching enzyme deficiency and storage of
limited dextrin. Patients with GSDIIIa show involvement of
liver and cardiac/skeletal muscle, whereas GSDIIIb patients
display only liver symptoms and signs. The International
Study on Glycogen Storage Disease (ISGSDIII) is a descrip-
tive retrospective, international, multi-centre cohort study of
diagnosis, genotype, management, clinical course and out-
come of 175 patients from 147 families (86 % GSDIIIa;
14 % GSDIIIb), with follow-up into adulthood in 91 patients.
In total 58 AGL mutations (non-missense mutations were
overrepresented and 21 novel mutations were observed) were
identified in 76 families. GSDIII patients first presented before
the age of 1.5 years, hepatomegaly was the most common
presenting clinical sign. Dietary management was very di-
verse and included frequent meals, uncooked cornstarch and
continuous gastric drip feeding. Chronic complications in-
volved the liver (hepatic cirrhosis, adenoma(s), and/or hepa-
tocellular carcinoma in 11 %), heart (cardiac involvement and
cardiomyopathy, in 58 % and 15 %, respectively, generally
presenting in early childhood), and muscle (pain in 34 %).
Type 2 diabetes mellitus was diagnosed in eight out of 91
adult patients (9%). In adult patients no significant correlation
was detected between (non-) missense AGL genotypes and
hepatic, cardiac or muscular complications. This study dem-
onstrates heterogeneity in a large cohort of ageing GSDIII
patients. An international GSD patient registry is warranted
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to prospectively define the clinical course, heterogeneity and
the effect of different dietary interventions in patients with
GSDIII.
Introduction
Glycogen storage disease type III (GSDIII; OMIM #232400)
is a rare inborn error of glycogen degradation with an inci-
dence of 1:100,000 (Dagli et al 2010; Kishnani et al 2010;
Laforêt et al 2012). GSDIII is caused by mutations in the AGL
gene and the subsequent deficiency of the glycogen
debranching enzyme (GDE; EC no. 3.2.1.33 and 2.4.1.25,
UniProt P35573). GDE contains two catalytic centres that
catalyse one of the last steps in the conversion of glycogen
to glucose-1-phosphate.
Patients with GSDIII present clinically with hepatomegaly,
failure to thrive and fasting intolerance, biochemically associ-
ated with ketotic hypoglycaemia. Phenotypically, patients can
be further classified into having either GSDIIIa (±85 %), with
involvement of the liver, heart and skeletal muscle, or
GSDIIIb (±15 %), in which only the liver is affected (Shen
et al 1996; Laforêt et al 2012). Dietary management aims to
maintain normoglycaemia and prevent hyperketonaemia by
dividing sufficient carbohydrate intake throughout the day,
and using additional protein as a substrate for gluconeogenesis
(as recently reviewed by Derks and Smit 2015). During long-
term follow-up the clinical focus shifts to the prevention and
management of progressive hepatic, cardiac and myopathic
complications (Dagli et al 2009; Sentner et al 2012; Verbeek
et al 2015).
Current knowledge on the clinical course and outcome has
been based on case reports and small single centre cohort
studies, of mainly young patients, on which the current man-
agement guidelines are based (Dagli et al 2010; Kishnani et al
2010). The International Study on GSDIII (ISGSDIII) is a
descriptive, retrospective, international, multi-centre cohort
study on the diagnosis, genotype, management, clinical course
and outcome in 175 patients with GSDIII, with follow-up into
adulthood in 91 patients.
Methods
The Medical Ethical Committee of the University Medical
Centre Groningen, the Netherlands approved the study proto-
col (ref.no. METc2008.035). Patients were included from 17
metabolic centres in ten countries. Between 2007 and 2011
data on GSDIII patients were collected using a case record
form (CRF) for every patient and anonymously archived in a
database. The CRF was based on the European Study on
GSDI (ESGSDI; Rake et al 2002), and modified for
ISGSDIII by two authors (GPAS, CPS) (for the complete
CRF, see Supplemental data 1). The CRFs were filled out
either by the treating physician or by one single investigator
(CPS).
GSDIII patients were included when an enzyme assay
and/or AGL molecular analysis had confirmed the diag-
nosis. GSDIIIa was defined as (a) deficient GDE activ-
ity in muscle or (b) clinical and/or biochemical signs of
cardiac and/or skeletal muscular involvement. Based on
the family history, individual patients could be catego-
rized as proband, symptomatic sibling or neonatally
screened patient due to an affected older sibling. To
study the relationship between AGL genotypes and
GSDIII phenotypes, statistical analyses were only per-
formed in adult patients. Cardiac involvement was de-
fined as the presence of abnormalities corresponding to
cardiac hypertrophy in the electrocardiographic and/or
echocardiographic investigations. Cardiomyopathy was
defined as the presence of cardiac hypertrophy in com-
bination with 1) (severe) exercise intolerance (and/or 2)
the use of pharmacological treatment for (symptoms of)
heart failure.
AGL mutations were grouped according to the type of mu-
tation, i.e. missense or non-missense AGL genotypes. Non-
missense mutations resulting in either frameshift or splicing
modifications were assumed to be pathogenic. Pathogenicity
of novel missense mutations was predicted by five methods:
Alamut Version 2.2 (©Interactive Biosoftware), PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.bii.
a-star.edu.sg/), whether the mutation was located in the
catalytic site (exon 6, 13-15, 26-27) or an exon encoding the
glycogen binding domain (exons 31-34), and the NHLBI
Exome Sequencing Project (ESP) Exome Variant Server
(http://evs.gs.washington.edu/EVS/).
Data were processed with IBM® SPSS® Statistics Version
20 (SPSS Inc., Chicago, Il, USA). The results were expressed
as median (range) for non-parametric data, and mean (stan-
dard deviation) for parametric data. Differences between nor-
mally distributed continuous data were analysed using the
unpaired two-tailed T-test. Not normally distributed data were
analysed using the Mann-Whitney-U or Kruskal-Wallis test.
For dichotomous data, the Fisher’s exact test was used. The
level of significance was set at p<0.05.
Results
Two hundred and twenty-eight patients with GSDIII
were identified. Data from 53 patients were incomplete
and not included in the analysis. Table 1 presents de-
mographic and diagnostic information on 175 patients
with GSDIII from 147 families, of whom 91 (52 %) had
reached adulthood.
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Clinical course and presentation until establishment
of the diagnosis
Pregnancy, birth and presenting symptoms Post-natal
hypoglycaemia was documented for six term, normal birth-
weight patients (3 %). In the 147 probands, the median age at
the first clinical presentation in GSDIIIa and GSDIIIb was at
0.7 year (range: day 1–8.1 years) and 1.0 year (range:
day 1–6.0 years), respectively. Common presenting symptoms
included hepatomegaly (98%), hypoglycaemia (53%), failure
to thrive (49 %) and recurrent illness and/or infections (17 %).
Mutation analysis Figure 1 presents the 58 individual report-
ed mutations, including 21 novel mutations, depicted per
exon/intron. AGL gene mutation analysis was performed in
76 out of 147 families, two causative mutations were identi-
fied in 72 families (95 %), in four families one allelic mutation
was identified. The majority (50/58; 86%) were non-missense
mutations resulting in a truncated protein. Among the pro-
bands in whom both affected alleles were identified, 47 were
found to be homozygotes, and 23 were compound heterozy-
gotes. No statistically significant correlation was recognized
between a (non-) missense AGL genotype and the occurrence
of major complications (hepatic, cardiac, myopathic) in 49
adult (≥18 years) patients.
Clinical course after establishment of the diagnosis
Figure 2 presents the age (median and range) of onset of clin-
ical features and complications.
Hepatic complications The overall prevalence of severe he-
patic complications (hepatic cirrhosis, adenomas and/or HCC)
was 11 % (19 out of 175 patients; one GSDIIIb; 12 females).
In 11 patients hepatic adenomas had been diagnosed (seven
females), two of these patients were overweight at the time of
diagnosis, and none of these patients used oral contraceptives.
Alpha-fetoprotein levels were measured for eight patients, in
none of these patients levels were over 40 ng/ml. In four
patients with hepatic cirrhosis, orthotopic liver transplantation
was performed at a median age of 32 years (15–35; three
females; one GSDIIIb). In two of these patients (one
GSDIIIb) hepatocellular carcinoma (HCC) was diagnosed
postoperatively upon pathological examination. Three pa-
tients in total had been diagnosed with HCC, all of whom
had progressed from hepatic fibrosis, to cirrhosis, and then
HCC.
Cardiac complications Cardiac involvement was reported in
58 % (87/151) of the GSDIIIa patients. Electrocardiographic
and/or echocardiographic signs of left ventricular hypertrophy
were found in 61 GSDIIIa patients. The remaining 26 patients
had other forms of cardiac hypertrophy (isolated septal, right
ventricular or biventricular hypertrophy). Cardiomyopathy
was reported in 15 % (22/151) of all GSDIIIa patients.
There were no laboratory parameters (cholesterol, triglycer-
ides, ASAT, ALAT, CK) significantly increased in GSDIIIa
patients with or without cardiomyopathy. Heart transplanta-
tions had not been performed in this cohort.
Neuromuscular complications Muscular pain after minimal
exercise was reported by 59 patients (34 %). Three patients
were wheelchair dependent due to skeletal muscle involve-
ment (signs of permanent muscle weakness with atrophy).
Electromyography (EMG) data were available from 33 pa-
tients and mainly showed myopathic changes, such as fibril-
lations and positive sharp waves. In 124 GSDIIIa patients
(81 %) CK concentrations were elevated at some point at a
median age of 10 years (0.3 – 56.1). Cardiomyopathy was
associated with a significantly higher prevalence of distal my-
opathy (Fisher’s exact p=0.034) and muscular pain after min-
imal exercise (Fisher’s exact p=0.030).
Growth and development Adult height was reached at a
median age of 19 years (15–23) (Table 2). There was no sig-
nificant difference between GSDIIIa and GSDIIIb patients
(p = 0.18). Of the patients who had reached adult height
24 % (21/86) had a BMI over 25 kg/m2 at the latest follow-
Table 1 Demographic and
diagnostic information of
GSDIIIa and GSDIIIb patients
GSDIIIa GSDIIIb Total
Demographic information
Male/female (n (%)) 69 (46 %)/82 (54 %) 13 (52 %)/11 (48 %) 82 (47 %)/93 (53 %)
Age (yrs: median (range)) 20.6 (1–64.1) 16.4 (0.3–50.7) 19.3 (0.3–64.2)
Follow-up (yrs: median (range)) 17.4 (0.5–61.1) 14.1(0.2 – 48.7) 16.2 (0.2–61.2)
Ethnicity (n)
Asian 2 1 3
Caucasian-Mediterranean 125 23 148
African-Caribbean 7 0 7
Mixed 17 0 17
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up, i.e. overweight according to WHO criteria. Pubertal de-
velopment was delayed in 36 patients, and there was no sig-
nificant difference between the subtypes (p = 0.72).
Furthermore, no significant difference was found in adult
height in SDS between the patients who had delayed com-
pared to normal pubertal development (p=0.15).
Bones Bone fractures were reported in 16 patients with
median age 7.5 years (range 1-18). According to WHO
criteria (T-scores), 14 GSDIIIa patients had normal bone
mineral density (BMD), 12 patients had osteopenia and
six patients had osteoporosis (all GSDIIIa patients).
Significantly increased CK (Kruskal-Wallis p = 0.004)
and ALAT (Kruskal-Wallis p=0.027) values were observed
in the osteoporosis group when compared with the normal
BMD-group.
Hyperlipidaemia Serum cholesterol and triglyceride concen-
trations were measured at the latest follow–up for 154 and 156
GSDIII patients, respectively. Cholesterol concentrations
were consistently elevated (>5.17 mmol/L) in 34 % of the
evaluated patients across different age groups. Triglyceride
concentrations were mainly elevated (>1.69 mmol/L) in early
childhood (in 23/29 79 %) patients up to 5 years. Between the
age of 5 and 15 years this incidence decreased to 72% (31/43),
and after the age of 15 years stabilized to 40 % (34/84).
Complications due to hyperlipidaemia, such as atherosclerosis
or pancreatitis, were not reported in this population.
Endocrinologic complications Type 2 diabetes mellitus
(DM2) was diagnosed in eight out of 91 adult patients (9 %;
all GSDIIIa), at median age of 38 years (32–44). Three pa-
tients were treated with insulin, and five with dietary
Fig. 1 AGL mutations in the ISGSDIII-cohort depicted per exon/intron
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Fig. 2 Age range of onset of disease features of GSDIII patients>
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adjustments. Four of these patients were overweight
(BMI >25 kg/m2). HCC was not reported in patients
with type 2 diabetes mellitus. Hirsutism was described
in one patient. Irregular menses or amenorrhea was described
in 19 patients. Polycystic ovaries were diagnosed by ultra-
sound in five patients at a median age of 19 years (6–30).
Mental and social development Mental development was
reported as normal in the majority of the patients, six patients
displayed low or borderline intelligence (3 %) and one patient
displayed severe developmental delay. Of the patients over
15 years of age (n=101), 50 patients (50 %) had normal em-
ployment and 23 patients (23 %) were following normal gen-
eral education. Sixteen patients (16 %) were unemployed,
with eight of these patients being unemployed due to mental
and/or physical disability. Thirty patients (21 females) had
64 healthy children.
Mortality Three patients with GSDIIIa had died because of
cardiomyopathy: one patient because of severe congestive
heart failure at the age of 1 year; and two patients because of
sudden cardiac death due to progressive cardiac fibrosis at the
age of 29 and 39 years, respectively (Ramachandran et al
2012). One patient with GSDIIIa died at the age of 36 years
because of severe liver failure due to end-stage hepatic cirrho-
sis in combination with hepatocellular carcinoma. One patient
died of causes unrelated to his GSD.
Dietary treatment
Dietary treatment at latest follow-up Information regarding
dietary treatment was collected on 171 patients (98 %; 87
children). Dietary restrictions were imposed on 16 patients;
lactose restriction in ten patients and fat intake restriction in
ten patients; 96 patients were reported to have a protein-
enriched diet. In children (n=49) the median cumulative pro-
tein intake was 2.9 grams per kilogram bodyweight per day
(gr/kg/d; range 0.5–4.4), and in adults (n = 47) the median
cumulative protein intake was 1.7 gr/kg/d (range 0.9–3.0).
Impaired dietary compliance was reported by the treating
physician and/or dietician in at least 29 patients (17 patients
aged<25 years).
History of dietary treatment One hundred forty-six patients
(83 %) were treated immediately after diagnosis. One hundred
twenty-two patients were treated with uncooked cornstarch
(UCCS) at some point; treatment with UCCS was stopped in
27 patients. Ninety-five patients were treated with UCCS at
the latest dietary adjustment (64 patients age <18 years). Fifty-
seven patients were treated with continuous gastric drip feed-
ing (CGDF) at some point; CGDF was stopped in 18 patients.
Thirty-nine patients were treated with CGDF at the lat-
est dietary adjustment (33 patients age <18 years). In
total 17 patients had received no dietary treatment at all
(nine patients age <25 years).
Discussion
ISGSDIII is a descriptive, retrospective, international, multi-
centre cohort study of 175 patients. This study addresses im-
portant issues regarding clinical presentation and follow-up
into adulthood.
Before discussing the results, some methodological issues
need to be addressed. First, as ISGSDIII is a retrospective
study, we have predominantly collected cross-sectional rather
than longitudinal patient data, and there has beenmissing data.
Unfortunately, IGSDIII did not collect data on fasting toler-
ance. Second, the ISGSDIII cohort is still relatively young,
and follow-up has not extended into adulthood for all patients.
This may have caused an underrepresentation of long-term
complications. Third, as most participating centres and col-
leagues are centre of expertise, selection bias towards relative-
ly severely affected patients may have affected the results.
Fourth, patients with the extremely rare subtypes GSDIIIc
(presumably the result of glucosidase debranching deficiency)
and GSDIIId (presumably the result of transferase
debranching deficiency) have not been included. Last, despite
the use of a CRF, in different centres clinical and laboratory
data are not yet recorded in a standardized and quantitative
manner (for instance dietary parameters, echocardiographic
parameters, quantification of skeletal muscle strength and ex-
ercise tolerance). Particularly the availability of dietary man-
agement data has been very limited. It additionally needs to be
recognized that there may be a difference between prescribed
diets and daily practice.
In contrast to the previous reports on GSDIII patients
(Dagli et al 2010; Kishnani et al 2010; Laforêt et al 2012),
ISGSDIII demonstrates that hypoglycaemia is a presenting
symptom in just half of the patients. Therefore, in patients
with a traditional clinical (hepatomegaly) and biochemical
(elevated transaminase values, hyperlipidaemia) presentation,
the diagnosis of GSDIII should not be rejected in the absence
Table 2 Height in SDS (compared to age-, gender- and ethnically
corrected reference values) at latest follow-up in all patients
Age group (yrs) N Median height SDS (range) N (%)< -2.0 SDS
0.0–2.0 10 −0.16 (-2.45–0.60) 1 (10)
2.0–5.0 20 −1.19 (-2.96–1.56) 2 (10)
5.0–10.0 27 −0.71 (-2.86–1.65) 5 (19)
10.0–15.0 24 −0.56 (-1.99–1.06) –
15.0–20.0 26 0.26 (-1.81–2.50) –
>20.0 61 0.13 (-2.86–2.46) 2 (3)
Total 168 −0.31 (-2.96–2.50) 10 (6)
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of (severe) hypoglycaemia. In addition, the finding of ketotic
hypoglycemia after short fasting test is a major argument for
GSDIII, as demonstrated recently (Hoogeveen et al 2015).
Severe mental retardation and mortality due to metabolic de-
rangement are uncommon in GSDIII patients. ESGSDI has
reported high morbidity and mortality because of metabolic
derangements with hypoglycaemia (Rake et al 2002). The
difference between these studies may be partially explained
by the relatively younger cohort of ISGSDIII. More impor-
tantly, there is a fundamental difference in metabolic compen-
sation between GSDI patients (alternative lactate accumulates
quickly, in the absence of ketones) and GSDIII patients (glu-
coneogenesis is intact and ketones can gradually be formed)
during fasting.
Clear genotype-phenotype correlations are rare in GSDIII.
The association between exon 3 mutations and GSDIIIb has
been reported previously (Shen et al 1996; Elpeleg 1999; Shen
and Chen 2002; Goldstein et al 2010). Interestingly, non-
missense AGL mutations are overrepresented in the
ISGSDIII cohort, whereas in most metabolic diseases
missense mutations predominate. It can be hypothesized
that missense mutations in the large AGL gene cause
only minor reduction of GDE enzyme activity. Moreover,
ISGSDIII demonstrates that GSDIIIa patients display a more
severe clinical course than GSDIIIb patients. The latter group
clinically presents at a later stage and has fewer complications,
such as hepatic cirrhosis and HCC. The large ISGSDIII cohort
did not identify additional correlations between AGL genotype
and severe complications.
In accordance with previous reports (Vertilus et al 2010)
ISGSDIII demonstrates that cardiac hypertrophy is common
in GSDIIIa patients, mostly starting in the first decade of life
(Fig. 2). Cardiac involvement remains stable over time in the
majority of the affected patients, with even a portion of the
patients regressing to normal values (data not presented).
Hence, functional and clinically relevant hypertrophic cardio-
myopathy is rare in GSDIIIa patients. Observations from
GSDIIIa patients with severe hypertrophic cardiomyopathy
suggest an important role of macronutrient intake (Derks and
Smit 2015). To date it is speculative which macronutrient
intervention is dominant, because each of the following has
been described, i.e. decreased total caloric intake (Sentner et al
2012), increased protein intake (Dagli et al 2009; Sentner et al
2012), increased fat intake (Brambilla et al 2014), ketone bod-
ies (Valayannopoulos et al 2011) and Atkins diet
(Mayorandan et al 2014). It is not possible to draw causative
conclusions from these single case observations, because
increasing one macronutrient (either protein or fat) without
affecting the other, inevitably affects the remaining macronu-
trient (carbohydrates). Based on at least two arguments it can
be hypothesized that carbohydrate overtreatment may be an
important risk factor for cardiac involvement and/or cardio-
myopathy. First, decreased carbohydrate intake was the
intervention shared by the above-mentioned reports in which
cardiomyopathy resolved after dietary intervention. Secondly,
decompensated structural cardiomyopathy is most frequently
reported around the time of highest endogenous glucose re-
quirements (i.e. childhood) and the prescription of relatively
high amounts of dietary carbohydrate.
ISGSDIII demonstrates that GSDIII patients have (severe)
growth retardation in (early) childhood, but eventually reach
normal adult height. There is no significant difference in
growth between GSDIIIa and GSDIIIb patients, suggesting
that the metabolic demands on gluconeogenesis in GSDIII in
general are more important than the presence of a muscular
GDE deficiency.
ISGSDIII demonstrates a high incidence of bone fractures
in paediatric GSDIII patients, suggesting the development of
reduced BMD at an early age. The pathophysiology of re-
duced BMD is unclear, but an association with specific nutri-
tional deficiencies in GSDIII (Folk and Greene 1984;
Kishnani et al 1999), and reduced metabolic control in
GSDI (Rake et al 2003) are mentioned. Recently, ALAT has
been suggested to be a marker for metabolic control in GSDIII
(Dagli et al 2010). ISGSDIII demonstrates a negative correla-
tion between osteopenia/osteoporosis and ALAT, supporting
the hypothesis that metabolic control affects BMD.
ISGSDIII reports a higher incidence of DM2 in ageing
GSDIII patients than in the general population (i.e. 9 %: com-
pared to 6 % in the general population in the western world
according to the World Diabetes Foundation). Previous case
reports and case studies have described the association be-
tween DM2 and GSDIII (Moe et al 1972; Oki et al 2000;
Ismail 2009; Sharma 2009; Spengos et al 2009) but the
aetiology is largely unknown. In the ISGSDIII cohort, half
of the diabetic patients are obese, suggesting that decreased
insulin sensitivity might play a role. Second, the constant in-
take of carbohydrate enriched nutrients to maintain
euglycaemia may induce insulin resistance.
Conclusions
ISGSDIII presents large heterogeneity between individual
GSDIII patients. Most GSDIII patients present clinically in
their first year of life with hepatomegaly as the major present-
ing symptom. From an acute disease in childhood, GSDIII
develops into a chronic, progressive disease in adulthood, af-
fecting liver, heart, skeletal muscle and bones. Chronic com-
plications and the risk of developing DM2 emphasize the need
of closely following the ageing GSDIII cohort. Standardized
quantitative clinical data collection is warranted by an inter-
national longitudinal GSD patient registry and biobank.
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